Retina

Astellas Pharma and 4D Molecular Therapeutics have entered into a license agreement that grants Astellas the rights to utilize 4DMT’s intravitreal retinotopic R100 vector for treating rare monogenic ophthalmic diseases.

VRDN-001 demonstrated positive preliminary results in the treatment of chronic thyroid eye disease in an ongoing phase 1/2 clinical trial, according to a press release from Viridian Therapeutics.

Jay S. Duker, MD, has been appointed as CEO of EyePoint Pharmaceuticals, and Nancy S. Lurker has transitioned from CEO to executive vice chair of the board of directors, according to a press release.

In this Healio Video Perspective from the Vit-Buckle Society annual meeting, Michelle Liang, MD, shares pearls on how retina specialists can help fellows feel comfortable in the OR.

The prevalence of diabetic retinopathy in the U.S. remains high and may continue to grow due to the increase in diabetes in patients of all ages, according to a study published in JAMA Ophthalmology.

OCT imaging is extremely valuable in the diagnosis and management of retinal conditions, providing high-resolution and repeatable images of retinal structures.

The American Academy of Ophthalmology recently expanded the depth and breadth of the IRIS Registry by including data from approximately 3.5 million real-world patient images.

Formycon and Klinge Biopharma have submitted a biologics license application for FYB203, a biosimilar for Eylea, to the FDA, according to a press release.

Patients who received aflibercept 8 mg for diabetic macular edema maintained dosing intervals through 2 years, according to a press release from Regeneron.